What is Hummingbird?
Preceptis Medical is a specialized medical device firm focused on the development of the Hummingbird Tympanostomy Tube System (TTS). This revolutionary technology enables ENT surgeons to perform pediatric ear tube placements in an office setting, eliminating the requirement for general anesthesia. By shifting the site of care, the company addresses significant pain points in the current healthcare landscape, including high costs and the inherent risks associated with pediatric sedation. The Hummingbird system is engineered to deliver a safer, more efficient, and cost-effective alternative to conventional surgical methods, yielding up to 65% in cost savings while facilitating a faster recovery for patients. The company's market position is defined by its commitment to clinical excellence and its ability to streamline common pediatric procedures, thereby enhancing the overall experience for both families and healthcare providers.
How much funding has Hummingbird raised?
Hummingbird has raised a total of $5.4M across 3 funding rounds:
Series A
$4.4M
Debt
$976K
Debt
$83K
Series A (2014): $4.4M, investors not publicly disclosed
Debt (2015): $976K, investors not publicly disclosed
Debt (2021): $83K supported by PPP
Key Investors in Hummingbird
Undisclosed Investor
An institutional partner providing strategic debt financing to support the company's operational growth and capital structure optimization.
PPP
Public-Private Partnership
Undisclosed Investor
A private investment group specializing in the healthcare sector, providing the necessary backing for early-stage medical device development.
What's next for Hummingbird?
With the recent influx of capital, Preceptis Medical is well-positioned to accelerate its commercialization strategy and expand its footprint within the pediatric ENT market. The company is expected to focus on scaling its sales infrastructure and increasing physician adoption of the Hummingbird platform. As the healthcare industry continues to prioritize value-based care and outpatient efficiency, the firm's ability to demonstrate significant cost reductions and improved patient outcomes will be critical to its long-term growth trajectory. Future strategic initiatives will likely involve deepening market penetration and potentially exploring further innovations in minimally invasive pediatric surgical technology to maintain its competitive edge in the medical device sector.
See full Hummingbird company page
